About the Authors

Peter Hoogerhout

Peter.Hoogerhout@rivm.nl

Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

Willem Kamphuis

Affiliation Netherlands Institute for Neuroscience (NIN), Astrocyte Biology & Neurodegeneration, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands

Humphrey F. Brugghe

Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

Jacqueline A. Sluijs

Affiliation Netherlands Institute for Neuroscience (NIN), Astrocyte Biology & Neurodegeneration, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands

Hans A. M. Timmermans

Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

Janny Westdijk

Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

Gijsbert Zomer

Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

Claire J. P. Boog

Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

Elly M. Hol

Affiliation Netherlands Institute for Neuroscience (NIN), Astrocyte Biology & Neurodegeneration, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands

Germie P. J. M. van den Dobbelsteen

Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

Competing Interests

The authors have read the journal's policy and have the following conflicts. PH and GPJMvdD have filed a patent application entitled “Vaccine against amyloid folding intermediate.” EP08159385.7 (2008), WO2010002251 (A1) (2010). The RIVM is a Government Institute. The application was filed on behalf of “the Kingdom of The Netherlands.” It does not alter the authors' adherence to the PLoS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: PH WK JW GZ EMH GPJMvdD. Performed the experiments: PH WK HFB JAS HAMT JW GZ. Analyzed the data: PH WK JW GZ CJPB EMH GPJMvdD. Contributed reagents/materials/analysis tools: PH WK HFB JAS HAMT JW GZ. Wrote the paper: PH WK EMH.